JAM3 and atherosclerosis: A principal finding of the present study was the correlation between the in-vitro data demonstrating alterations in JAM-C expression and functional increases in monocyte rTEM (and migration velocity), and the in-vivo atherosclerosis model, where JAM-C blockade increased leukocyte emigration from plaques, which accelerated the regression of the inflammatory lesion.